In the context of these and other findings, subsets of high-risk prostate cancers with positive DNA repair deregulation may potentially benefit from the combination of androgen deprivation, which is currently standard of care, with PARP inhibitors to enhance tumor control. Here, PARP1 is linked to prostate carcinoma.